Cargando…
A New Perspective on Cancer Therapy: Changing the Treaded Path?
During the last decade, we have persistently addressed the question, “how can the innate immune system be used as a therapeutic tool to eliminate cancer?” A cancerous tumor harbors innate immune cells such as macrophages, which are held in the tumor-promoting M2 state by tumor-cell-released cytokine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466953/ https://www.ncbi.nlm.nih.gov/pubmed/34575998 http://dx.doi.org/10.3390/ijms22189836 |
_version_ | 1784573272619220992 |
---|---|
author | Baidoo, Juliet N. E. Mukherjee, Sumit Kashfi, Khosrow Banerjee, Probal |
author_facet | Baidoo, Juliet N. E. Mukherjee, Sumit Kashfi, Khosrow Banerjee, Probal |
author_sort | Baidoo, Juliet N. E. |
collection | PubMed |
description | During the last decade, we have persistently addressed the question, “how can the innate immune system be used as a therapeutic tool to eliminate cancer?” A cancerous tumor harbors innate immune cells such as macrophages, which are held in the tumor-promoting M2 state by tumor-cell-released cytokines. We have discovered that these tumor-associated macrophages (TAM) are repolarized into the nitric oxide (NO)-generating tumoricidal M1 state by the dietary agent curcumin (CC), which also causes recruitment of activated natural killer (NK) cells and cytotoxic T (Tc) cells into the tumor, thereby eliminating cancer cells as well as cancer stem cells. Indications are that this process may be NO-dependent. Intriguingly, the maximum blood concentration of CC in mice never exceeds nanomolar levels. Thus, our results submit that even low, transient levels of curcumin in vivo are enough to cause repolarization of the TAM and recruitment NK cells as well as Tc cells to eliminate the tumor. We have observed this phenomenon in two cancer models, glioblastoma and cervical cancer. Therefore, this approach may yield a general strategy to fight cancer. Our mechanistic studies have so far implicated induction of STAT-1 in this M2→M1 switch, but further studies are needed to understand the involvement of other factors such as the lipid metabolites resolvins in the CC-evoked anticancer pathways. |
format | Online Article Text |
id | pubmed-8466953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84669532021-09-27 A New Perspective on Cancer Therapy: Changing the Treaded Path? Baidoo, Juliet N. E. Mukherjee, Sumit Kashfi, Khosrow Banerjee, Probal Int J Mol Sci Opinion During the last decade, we have persistently addressed the question, “how can the innate immune system be used as a therapeutic tool to eliminate cancer?” A cancerous tumor harbors innate immune cells such as macrophages, which are held in the tumor-promoting M2 state by tumor-cell-released cytokines. We have discovered that these tumor-associated macrophages (TAM) are repolarized into the nitric oxide (NO)-generating tumoricidal M1 state by the dietary agent curcumin (CC), which also causes recruitment of activated natural killer (NK) cells and cytotoxic T (Tc) cells into the tumor, thereby eliminating cancer cells as well as cancer stem cells. Indications are that this process may be NO-dependent. Intriguingly, the maximum blood concentration of CC in mice never exceeds nanomolar levels. Thus, our results submit that even low, transient levels of curcumin in vivo are enough to cause repolarization of the TAM and recruitment NK cells as well as Tc cells to eliminate the tumor. We have observed this phenomenon in two cancer models, glioblastoma and cervical cancer. Therefore, this approach may yield a general strategy to fight cancer. Our mechanistic studies have so far implicated induction of STAT-1 in this M2→M1 switch, but further studies are needed to understand the involvement of other factors such as the lipid metabolites resolvins in the CC-evoked anticancer pathways. MDPI 2021-09-11 /pmc/articles/PMC8466953/ /pubmed/34575998 http://dx.doi.org/10.3390/ijms22189836 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Opinion Baidoo, Juliet N. E. Mukherjee, Sumit Kashfi, Khosrow Banerjee, Probal A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title | A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title_full | A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title_fullStr | A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title_full_unstemmed | A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title_short | A New Perspective on Cancer Therapy: Changing the Treaded Path? |
title_sort | new perspective on cancer therapy: changing the treaded path? |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466953/ https://www.ncbi.nlm.nih.gov/pubmed/34575998 http://dx.doi.org/10.3390/ijms22189836 |
work_keys_str_mv | AT baidoojulietne anewperspectiveoncancertherapychangingthetreadedpath AT mukherjeesumit anewperspectiveoncancertherapychangingthetreadedpath AT kashfikhosrow anewperspectiveoncancertherapychangingthetreadedpath AT banerjeeprobal anewperspectiveoncancertherapychangingthetreadedpath AT baidoojulietne newperspectiveoncancertherapychangingthetreadedpath AT mukherjeesumit newperspectiveoncancertherapychangingthetreadedpath AT kashfikhosrow newperspectiveoncancertherapychangingthetreadedpath AT banerjeeprobal newperspectiveoncancertherapychangingthetreadedpath |